peptide 14

General Information


DRACP ID  DRACP02578

Peptide Name   peptide 14

Sequence  XXWXXXWWX

Sequence Length  9

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetic

Type  Synthetic peptide

Classification

  

Active ACP Membrane lysis



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
A20 Murine B cell lymphoma Lymphoma IC50=8.3 ± 0.6 µM MTT assay 4 h 1
AT84 Murine squamous cell carcinoma Carcinoma IC50=14.3 ± 1.2 µM MTT assay 4 h 1

Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  MRC-5: IC50=97.7 ± 5.1 µM

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer



Structure Information


PDB ID  Not available

Predicted Structure  Not available

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Amidation

Other Modification  X=Dab ((S)-2,4-diaminobutyric acid)

Chiral  L



Physicochemical Information


Formula  C33H20N6O-2

Absent amino acids  ACDEFGHIKLMNPQRSTVY

Common amino acids  X

Mass  127143

Pl  6.11

Basic residues  0

Acidic residues  0

Hydrophobic residues  3

Net charge  0

Boman Index  699

Hydrophobicity  -30

Aliphatic Index  0

Half Life 
  /

Extinction Coefficient cystines  16500

Absorbance 280nm  2062.5

Polar residues  0

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 26982623

Title  Discovery of a 9-mer Cationic Peptide (LTX-315) as a Potential First in Class Oncolytic Peptide

Doi 10.1021/acs.jmedchem.5b02025

Year  2016

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DBAASP ID  DBAASPS_11903

DRACP is developed by Dr.Zheng's team.